Renaissance Capital logo

PCRX News

Pacira Pharma quiet period ends March 14

Pacira Pharmaceuticals, which is developing a non-opioid postsurgical analgesic pending FDA approval, will see its quiet period end on Monday, March 14. On February 2, the company raised $42 million by offering 6 million shares at $7, below the original range...read more

Pacira Pharmaceuticals prices IPO at $7, well below its initially proposed range

Pacira Pharmaceuticals, which is developing a non-opioid postsurgical analgesic pending FDA approval, raised $42 million by offering 6 million shares at $7, as outlined in an SEC amendment filed earlier today. The biotech had originally expected to sell 4.25...read more

Pacira Pharmaceuticals offers more shares, slashes proposed IPO price

Pacira Pharmaceuticals, which is developing a non-opioid postsurgical analgesic pending FDA approval, lowered the proposed deal size for its upcoming IPO on Wednesday. The Parsippany, NJ-based company now plans to raise $42 million by offering 6 million shares...read more

Pacira Pharmaceuticals sets terms for $64 million IPO

Pacira Pharmaceuticals, a pharmaceutical company developing a non-opioid postsurgical analgesic, announced terms for its IPO on Thursday. The Parsippany, NJ-based company plans to raise $64 million by offering 4.25 million shares at a price range of $14-$16. ...read more

Archived Headlines